2. Academic Validation
  3. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors

Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  • Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83. doi: 10.1016/j.bmcl.2010.01.008.
Hassan Pajouhesh 1,  Zhong-Ping Feng,  Yanbing Ding,  Lingyun Zhang,  Hossein Pajouhesh,  Jerrie-Lynn Morrison,  Francesco Belardetti,  Elizabeth Tringham,  Eric Simonson,  Todd W Vanderah,  Frank Porreca,  Gerald W Zamponi,  Lester A Mitscher,  Terrance P Snutch
Affiliations

Affiliation

  • 1 Neuromed Pharmaceuticals Ltd, 301-2389 Health Sciences Mall, Vancouver, BC, Canada.
PMID: 20117000 DOI: 10.1016/j.bmcl.2010.01.008
Abstract

A novel series of compounds derived from the previously reported N-type Calcium Channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC(50) values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.

Figures
Products